
Références
- Rozenblum AB et al._ Clinical Impact of Hybrid Capture–Based Next-Generation Sequencing on Changesin Treatment Decisions in Lung Cancer_ J Thorac Oncol_2017; 12: 258–268.
- Schwaederle M et al._ Precision Oncology: The UC San Diego Moores Cancer Center PREDICT Experience_ Mol Cancer Ther_2016; 15: 743–752.
- Mansinho A et al._ The future of oncology therapeutics_ Expert Rev Anticancer Ther_2017; 17: 563–565.
- Frampton GM et al._Development and validation of a clinical cancergenomic profiling test based on massively parallel DNA sequencing_ Nat Biotechnol_2013; 31: 1023–1031.
- Drilon A et al._ Broad, hybrid capture-based next-generation sequencing identifies actionable genomic alterations in “driver-negative”lung adenocarcinomas_ Clin Cancer Res_2015; 21: 3631–3639.
- Hirsch FR et al._ New and emerging targeted treatments in advanced non-small-cell lung cancer_Lancet_2016; 388: 1012–1024.
- Baumgart M._ New Molecular Targets on the Horizon in Non-Small Cell Lung Cancer_ Am J Hematol Oncol_2015; 11: 10–13.
- Chakravarty D et al._ OncoKB: A Precision Oncology Knowledge Base_ JCO Precis Oncol_2017; doi: 10.1200/PO.17.00011. [Epub ahead of print].
- Global Oncology Trends Report 2018. Report by IQVIA Institute for Human Data Science. Disponible sur : https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-oncology-trends-2018.pdf (Publié Octobre 2018).
- Gagan J, Van Allen EM._ Next-generation sequencing to guide cancer therapy_ Genome Med_2015; 7: 80.
- Schrock AB et al._ Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing_ Clin Cancer Res_2016; 22: 3281–3285.
- Rankin A et al._ Broad Detection of Alterations Predicted to Confer Lackof Benefit FromEGFR Antibodies or Sensitivity to Targeted Therapy in AdvancedColorectal Cancer_Oncologist_2016; 21: 1306–1314.
- Suh JH et al._ Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials_Oncologist_2016; 21: 684–691.
- Chalmers ZR et al._ Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden_Genome Med_2017; 9: 34.
- Goodman AM et al._ Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers_Mol Cancer Ther_2017; 16: 2598–2608.
- Le DT et al._ Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade_ Science_2017; 357: 409-413.
- Johnson DB et al._ Targeted next generation sequencing identifies markers of response to PD-1 blockade_Cancer Immunol Res_2016; 4: 959–967.
- Rizvi H et al._ Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing_J Clin Oncol_2018; 36: 633–641.
- Hellmann MD et al. N Engl J Med 2018; 378: 2093–2104.
- &NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Non-Small Lung Cancer. V.5.2018, 2018. Disponible sur : https://www.nccn.org/professionals/physician_gls/recently_updated.aspx (Publié Octobre 2018).
- Kalemkerian GP et al._ Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/ International Association for the Study of Lung Cancer/ Association for Molecular Pathology Clinical Practice Guideline Update_J Clin Oncol_2018; 36: 911–919.
- Lindeman NI et al_ Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors_ J Mol Diagn_2018; 20: 129–159.